DOP2017000209A - Derivados de heteroarilo bicíclico fusionados con actividad como inhibidores de phd - Google Patents

Derivados de heteroarilo bicíclico fusionados con actividad como inhibidores de phd

Info

Publication number
DOP2017000209A
DOP2017000209A DO2017000209A DO2017000209A DOP2017000209A DO P2017000209 A DOP2017000209 A DO P2017000209A DO 2017000209 A DO2017000209 A DO 2017000209A DO 2017000209 A DO2017000209 A DO 2017000209A DO P2017000209 A DOP2017000209 A DO P2017000209A
Authority
DO
Dominican Republic
Prior art keywords
heteroaril
bicyclic
fused
derivatives
activity
Prior art date
Application number
DO2017000209A
Other languages
English (en)
Spanish (es)
Inventor
Livermore David
Ahmed Saleh
Canning Hannah
Harrison David
Jenkins Kerry
Wright Susanne
Kinsella Natasha
Barker Gregory
Davenport Richard
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of DOP2017000209A publication Critical patent/DOP2017000209A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
DO2017000209A 2015-03-18 2017-09-18 Derivados de heteroarilo bicíclico fusionados con actividad como inhibidores de phd DOP2017000209A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1504565.1A GB201504565D0 (en) 2015-03-18 2015-03-18 Novel compounds

Publications (1)

Publication Number Publication Date
DOP2017000209A true DOP2017000209A (es) 2017-10-15

Family

ID=53051992

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2017000209A DOP2017000209A (es) 2015-03-18 2017-09-18 Derivados de heteroarilo bicíclico fusionados con actividad como inhibidores de phd

Country Status (31)

Country Link
US (1) US10287286B2 (enExample)
EP (1) EP3271357B1 (enExample)
JP (1) JP6726681B2 (enExample)
KR (1) KR102609431B1 (enExample)
CN (1) CN107531698B (enExample)
AU (1) AU2016234209B2 (enExample)
BR (1) BR112017019653B1 (enExample)
CA (1) CA2979024C (enExample)
CL (1) CL2017002354A1 (enExample)
CO (1) CO2017009353A2 (enExample)
CR (1) CR20170468A (enExample)
DK (1) DK3271357T3 (enExample)
DO (1) DOP2017000209A (enExample)
EA (1) EA035739B1 (enExample)
EC (1) ECSP17069696A (enExample)
ES (1) ES2774052T3 (enExample)
GB (1) GB201504565D0 (enExample)
GE (1) GEP20207095B (enExample)
HU (1) HUE047918T2 (enExample)
IL (1) IL254277B (enExample)
MX (1) MX2017011902A (enExample)
MY (1) MY194873A (enExample)
NZ (1) NZ735631A (enExample)
PE (1) PE20180656A1 (enExample)
PH (1) PH12017501699B1 (enExample)
PT (1) PT3271357T (enExample)
SG (1) SG11201707280VA (enExample)
TN (1) TN2017000384A1 (enExample)
UA (1) UA123668C2 (enExample)
WO (1) WO2016148306A1 (enExample)
ZA (1) ZA201706612B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3419978T2 (ro) 2016-02-24 2020-07-31 Pfizer Derivaţi de pirazolo[1,5-a]pirazin-4-il
WO2019034973A1 (en) 2017-08-14 2019-02-21 Pfizer Inc. PYRAZOLO [1,5-A] PYRAZIN-4-YL AND RELATED DERIVATIVES
SG11202102441VA (en) * 2018-09-13 2021-04-29 Kissei Pharmaceutical Co Ltd Imidazopyridinone compound
CN110950806A (zh) * 2019-11-14 2020-04-03 安庆博曼生物技术有限公司 四乙基氯化铵催化嘧啶环羟基氯代制备方法
JP7504822B2 (ja) * 2020-03-12 2024-06-24 キッセイ薬品工業株式会社 イミダゾピリジノン化合物を含む医薬組成物
US11718622B2 (en) 2020-03-16 2023-08-08 Exelixis Inc. Heterocyclic adenosine receptor antagonists
CN117304171A (zh) * 2020-04-20 2023-12-29 深圳市塔吉瑞生物医药有限公司 吡嗪取代的烟酰胺的固体形式及其制备和用途
WO2022083569A1 (en) * 2020-10-20 2022-04-28 Amgen Inc. Heterocyclic spiro compounds and methods of use
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
US20250034132A1 (en) 2021-10-28 2025-01-30 Insilico Medicine Ip Limited Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof
CN118715015A (zh) * 2021-12-17 2024-09-27 阿克比治疗有限公司 选择性phd1抑制剂化合物、组合物和使用方法
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4209621A (en) 1979-04-27 1980-06-24 American Cyanamid Company (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines
DK135184A (da) 1983-03-03 1984-10-10 Riker Laboratories Inc Triazol(4,3-c)- og triazol(1,5-c)pyrimidiner
US4572910A (en) * 1983-03-03 1986-02-25 Riker Laboratories, Inc. Triazolo[1,5-c]pyrimidines substituted by nitrogen-containing heterocyclic rings
EA006483B1 (ru) 2000-06-30 2005-12-29 Уайт Замещенные триазолопиримидины в качестве противораковых средств
JP2010065026A (ja) 2008-08-13 2010-03-25 Ishihara Sangyo Kaisha Ltd ピリジル−トリアゾロピリミジン誘導体又はその塩、並びにそれらを含有する有害生物防除剤
JP2010065024A (ja) 2008-08-14 2010-03-25 Ishihara Sangyo Kaisha Ltd トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤
US8283465B2 (en) * 2009-07-17 2012-10-09 Japan Tobacco Inc. Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent
JP2011168582A (ja) 2010-01-21 2011-09-01 Ishihara Sangyo Kaisha Ltd トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤
WO2014030716A1 (ja) * 2012-08-23 2014-02-27 田辺三菱製薬株式会社 ピラゾロピリミジン化合物

Also Published As

Publication number Publication date
CL2017002354A1 (es) 2018-05-04
WO2016148306A1 (en) 2016-09-22
HK1249512A1 (en) 2018-11-02
ES2774052T3 (es) 2020-07-16
CO2017009353A2 (es) 2017-11-30
MX2017011902A (es) 2017-12-15
UA123668C2 (uk) 2021-05-12
CA2979024A1 (en) 2016-09-22
GB201504565D0 (en) 2015-05-06
BR112017019653A2 (pt) 2018-05-15
CN107531698B (zh) 2024-08-13
PT3271357T (pt) 2020-02-21
IL254277B (en) 2020-10-29
BR112017019653B1 (pt) 2023-10-03
MY194873A (en) 2022-12-21
GEP20207095B (en) 2020-04-10
EA035739B1 (ru) 2020-08-03
AU2016234209A1 (en) 2017-10-12
CR20170468A (es) 2018-04-27
DK3271357T3 (da) 2020-02-17
CN107531698A (zh) 2018-01-02
KR20170129874A (ko) 2017-11-27
JP2018512408A (ja) 2018-05-17
AU2016234209B2 (en) 2020-08-27
PE20180656A1 (es) 2018-04-17
IL254277A0 (en) 2017-10-31
JP6726681B2 (ja) 2020-07-22
HUE047918T2 (hu) 2020-05-28
TN2017000384A1 (en) 2019-01-16
ZA201706612B (en) 2019-01-30
PH12017501699B1 (en) 2023-06-30
KR102609431B1 (ko) 2023-12-04
ECSP17069696A (es) 2018-02-28
PH12017501699A1 (en) 2018-03-12
EA201792057A1 (ru) 2018-04-30
US20180072714A1 (en) 2018-03-15
EP3271357A1 (en) 2018-01-24
US10287286B2 (en) 2019-05-14
CA2979024C (en) 2024-02-20
EP3271357B1 (en) 2019-11-27
NZ735631A (en) 2023-07-28
SG11201707280VA (en) 2017-10-30

Similar Documents

Publication Publication Date Title
DOP2017000209A (es) Derivados de heteroarilo bicíclico fusionados con actividad como inhibidores de phd
ECSP16074478A (es) Compuestos novedosos
SV2017005514A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
MX2018003432A (es) Compuestos heterociclicos y usos de los mismos.
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
ECSP17074645A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
MX381707B (es) Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
NI201400107A (es) Compuestos de heterociclilo como inhibidores de mek
DOP2015000158A (es) Inhibidores de prmt5 y sus usos
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
MX2018000280A (es) Oxiesteroles y metodos de uso de los mismos.
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
CR20160084A (es) Derivados de amida como agonistas del receptor del ácido lisofosfatídico
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
CU20180028A7 (es) DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
ECSP16074482A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
UY35536A (es) ?derivados de sulfonamida?.
ECSP18056196A (es) Derivados de indano
AR132461A2 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
UY35672A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos